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To the Editor:
The recently published article by 
Scagliotti et al.1 reports the results of an 
explorative study performed on a subset 
of patients with bone metastatic lung 
cancer, enrolled in a large, prospec-
tive, phase III trial, which compared the 
efficacy of denosumab plus standard 
antineoplatic therapy versus zoledronic 
acid plus standard therapy. The results 
showed that denosumab-treated patients 
obtained a significant survival improve-
ment over zoledronic acid-treated ones. 
The greater potency of denosumab 
than zoledronic acid in decreasing 
bone turnover is conceivably the major 
mechanism responsible for the results 
obtained, so these data further underline 
the importance of targeting bone micro-
environment in the management of 
patients with metastatic cancer. In the 
two randomized clinical trials with the 
same design, conducted in patients with 
breast and prostate cancer,2,3 however, 
denosumab failed to demonstrate a sur-
vival advantage over zoledronic acid. 
How can we explain this discrepancy? 
All these trials showed that the greater 
bone turnover inhibition induced by 
denosumab led to a greater incidence 
of hypocalcemia than zoledronic acid. 
However, hypocalcemia was more fre-
quent in patients with bone lesions with 
a greater blastic component, that is, 
13% in prostate cancer versus 8.6% in 
lung cancer patients after denosumab 
(the frequency of hypocalcemia in the 
breast cancer trial was not reported). 
The consequence of hypocalcemia is 
secondary hyperparathyroidism and 
this condition can adversely affect the 
efficacy of bone resorption inhibitors 
by several mechanisms: (1) parathyroid 
hormone (PTH) increases the availabil-
ity of cytokines and growth factors in 
bone microenvironment, (2) PTH has 
an amino-terminal sequence homol-
ogy with PTH-related protein, a potent 
growth factor, and PTH-related pro-
tein and PTH bind to the same recep-
tor that is expressed in cancer cells. In 
an explorative analysis performed on 
the data of a multinational trial of bone 
metastatic prostate cancer patients who 
were randomized to receive zoledronic 
acid or placebo,4 secondary hyperpara-
thyroidism was a negative predictor 
of zoledronic acid efficacy in terms of 
survival. On these grounds, an interest-
ing hypothesis is that secondary hyper-
parathyroidism may limit the efficacy 
of denosumab. If this hypothesis is 
true, then a vitamin D supplementation 
tailored to counteract individual hypo-
calcemia can improve the drug efficacy 
in terms of survival. In the explorative 
study by Scagliotti et al.,1 therefore, it 
would be interesting to know whether 
the efficacy of denosumab versus zole-
dronic acid is improved in the patient 
subset that did not experience hypo-
calcemia after denosumab, as opposed 
to those patients developing this meta-
bolic disturbance.
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To the Editor:
The combination of platinum-
compounds and pemetrexed has 
recently become the standard of care 
in the first-line treatment of malignant 
pleural mesothelioma (MPM). Because 
not all the patients benefit, predic-
tive biomarkers of pemetrexed activ-
ity are critical for tailored treatments. 
However, pharmacogenetic studies on 
genotyping or expression profiles were 
controversial. A possible explanation 
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